3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Multiple Myeloma
76
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Burkitt Lymphoma
16
Recurrence
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Neoplasms, Plasma Cell
5
Lymphoma
5
Leukemia, Biphenotypic, Acute
5
Immunoglobulin Light-chain Amyloidosis
5
Smoldering Multiple Myeloma
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Leukemia
4
Neoplasm Metastasis
3
Down Syndrome
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Waldenstrom Macroglobulinemia
2
Prostatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Leukemia, Hairy Cell
2
Hodgkin Disease
2
Fatigue
2
Brain Neoplasms
2
Blastic Plasmacytoid Dendritic Cell Neoplasm
2
Interventions
enzalutamide
94
Magnetic Resonance Spectroscopy
85
Specimen Handling
66
Prednisone
63
Androgen Antagonists
59
Abiraterone Acetate
57
apalutamide
55
Radiosurgery
52
darolutamide
48
Radiotherapy
47
Leuprolide
46
abiraterone
45
Docetaxel
42
Pluvicto
32
Biopsy
31
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
30
Radiation
30
relugolix
28
Surveys and Questionnaires
28
gallium 68 PSMA-11
26
Standard of Care
26
pembrolizumab
25
Goserelin
25
Triptorelin Pamoate
24
Gonadotropin-Releasing Hormone
23
bicalutamide
22
Brachytherapy
21
Carboplatin
20
cabazitaxel
19
X-Rays
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Calcium Dobesilate
×
1 year
×
Clear all
NCT06104449
2026-04-27
MK-5684-005
Merck Sharp & Dohme LLC
Phase 1
Completed
7 enrolled
NCT03834506
2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Completed
1,030 enrolled
24 charts